# Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

> **NCT01573468** · PHASE2 · UNKNOWN · sponsor: **Genta Incorporated** · enrollment: 580 (estimated)

## Conditions studied

- Gastric Carcinoma

## Interventions

- **DRUG:** Tesetaxel
- **DRUG:** Placebo
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01573468
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-04
- **Primary completion:** 2014-07
- **Final completion:** 2014-08
- **Target enrollment:** 580 (ESTIMATED)
- **Last updated:** 2012-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01573468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01573468, "Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01573468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*